相关实验视频

Updated: Jan 8, 2026

Author Spotlight: Advancing the Analysis of Plasma Extracellular Vesicle Proteome for Cardiovascular Biomarker Studies

Author Spotlight: Advancing the Analysis of Plasma Extracellular Vesicle Proteome for Cardiovascular Biomarker Studies

Published on: January 31, 2025

解读血蛋白质组:在心血管健康方面推进精准医学

Hector A Cabrera-Fuentes¹, Elisa A Liehn², Ebtesam A Al-Suhaimi³

¹División de Estudios de Posgrado e Investigación, Tecnológico Nacional de México/Instituto Tecnológico de Tijuana 22414 Tijuana, B.C, Mexico; R&D Group, Vice Presidency for Scientific Research and Innovation, Imam Abdulrahman Bin Faisal University, P.O. Box 1982, Dammam 31441, Saudi Arabia; UNAM-UABJO Research Centre, Faculty of Medicine and Surgery, Universidad Autónoma Benito Juárez de Oaxaca (UABJO), Oaxaca 68120, Mexico; División de Investigación y Desarrollo Científico, Benemérita Universidad de Oaxaca, Oaxaca 68000, Mexico.

Drug discovery today

|December 14, 2025

概括

血蛋白质组通过识别潜在的药物标来帮助心血管疾病研究. 一个严格的,多步骤的管道确保这些发现可靠地转化为有效的精确疗法.

科学领域:

生物化学生物化学
遗传学是一个遗传学.
药理学药理学是指药理学的学科.

背景情况:

血蛋白质组为人类生理学提供了洞察力,这对于生物标志物发现和心血管疾病中药物开发至关重要.
高通量技术,基因绘图和机器学习识别了潜在的治疗点,但需要验证临床转化.

研究的目的:

为心血管治疗提出一个严格的,分层的管道来验证血蛋白质组的发现.
概述加速开发可复制和公平的精确心血管药物的方法.

主要方法:

一个多阶段的方法,包括发现,直角确认 (质谱/免疫检测),遗传优先 (colocalization/敏感性分析) 和功能验证.
与多omics数据,多样化的患者队列和使用HL7 FHIR和OHDSI CDM的电子健康记录的整合.

主要成果:

拟议的管道提高了将蛋白质组发现转化为临床应用的可靠性.
整合策略有助于加速可重复和公平的精准医学发展.

结论:

系统的,多层次的验证策略对于将血蛋白质组发现转化为心血管疗法至关重要.
利用多种药物,多样化的数据和标准化的健康记录实施加速了精确心血管药物的开发.

关键词:

心血管疾病心血管疾病血蛋白质是血中的蛋白质.类型的类型.精准医学是一门精准医学.蛋白质组学蛋白质组学治疗目标是治疗的目标.

更多相关视频

Optimized Protocol for the Extraction of Proteins from the Human Mitral Valve

Optimized Protocol for the Extraction of Proteins from the Human Mitral Valve

Published on: June 14, 2017

Basic Research in Plasma Medicine - A Throughput Approach from Liquids to Cells

Basic Research in Plasma Medicine - A Throughput Approach from Liquids to Cells

Published on: November 17, 2017

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

Proteomics

Proteomics

A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...